Intoxicación aguda y crónica | Arsénico
Uno de los metales más tóxicos proveniente del entorno natural.
Uncategorized
¿Cuál es su utilidad clínica en el mundo real? | Eritrosedimentación y Proteína C Reactiva en el servicio de urgencias
Son reactivos de fase aguda con concentraciones que cambian en respuesta a la inflamación, tanto de forma aguda como crónica
Ciclo de entrevistas “invisibles” | Historia del Hospital Noé Yarcho, donde ejerció el “médico milagroso” de las colonias judías
Sito en Villa Domínguez, provincia de Entre Ríos, se emplazó con la llegada de los primeros colonos y hasta se sostuvo por los vecinos durante años. Hoy atiende a cerca de 600 pacientes mensuales. Todo sobre su pasado y presente.
Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive long-term follow-up data from the pivotal, Phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant (before surgery) treatment.
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 genome-edited cell therapy, for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).
RevBio Receives FDA Approval to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation
RevBio, Inc., announced that it has received approval from the U.S. Food and Drug Administration to start a 20-patient pilot clinical trial to examine the safety and efficacy of the company’s bone adhesive biomaterial called TETRANITE® to immediately stabilize and fixate cranial flaps following craniotomy procedures associated with brain surgery.
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab). ELREFXIO is a targeted immunotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody and have demonstrated
Henry Schein says 29K people affected in September cyber incident
The ransomware group AlphV/BlackCat has claimed responsibility for the data breach and a second incident involving the company.
Henry Schein says 29K people affected in September cyber incident Read More »
Hospital lobbies push back on site-neutral provision in House bill
The American Hospital Association and the Federation of American Hospitals sent letters to Congress this week opposing a bill that would equalize payments for drugs administered in outpatient clinics.
Hospital lobbies push back on site-neutral provision in House bill Read More »
Senators probe private equity’s role in hospital operations
The inquiry comes as the White House this week said it would investigate private equity investment in healthcare as federal scrutiny of firms ramps up.
Senators probe private equity’s role in hospital operations Read More »